The FDA has approved Gilead Sciences Inc’s antiviral drug remdesivir for treating patients hospitalized with COVID-19, making it the first and only drug approved for the disease in the United States.
A number of recently published clinical trials are further defining the efficacy and outcomes of tocilizumab or remdesivir in treating SARs-CoV-2 infection.
Remdesivir
The COVID-19 pandemic dramatically impacted outpatient care - numbers, scope, quality, etc, but a recent study suggests that while COVID has changed the scope of care, the numbers of outpatient visits have risen to near pre-pandemic numbers.
Dr. Jack Cush sings the news and journal reports from the past week on RheumNow.com.
The CDC has analyzed temporal trends in percent positivity by age group in COVID-19 hotspot counties before and after their identification as hotspots.
The NEJM reports on a controlled clinical trial showing patients hospitalized with Covid-19 given hydroxychloroquine (HCQ) do not have a lower incidence of death compared to those receiving routine care.
Dr. Jack Cush Reviews the news and journal articles from the past week on RheumNow.com.
JAMA Internal Medicine reports an analysis of COVID-19 clinical trials showing that critically ill patients with COVID-19 treated with systemic corticosteroids have an overall lower mortality rate.
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Numerous previous studies have questioned the efficacy or protection afforded by hydroxychloroquine (HCQ) for COVID-19 and studies have show that HCQ has failed when given as post-exposure prophylaxis to health care workers (HCWs). A new randomized controlled trial has shown that HCQ failed when
CDC reports that since June 2020 individuals infected with COVID-19 have largely been young adults in the 20-29 year age bracket.
JAMA Dermatology expands the spectrum of complications seen with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection describing cutaneous purpura and livedo lesions in patients with severe COVID-19.
Links:
Dr. John Cush RheumNow( View Tweet)
Links:
Dr. John Cush RheumNow( View Tweet)
Links:
Dr. John Cush RheumNow( View Tweet)
Dr. John Cush RheumNow( View Tweet)
Links:
Dr. John Cush RheumNow( View Tweet)
Dr. John Cush RheumNow( View Tweet)
Links:
NYT Health NYTHealth( View Tweet)
Links:
Dr. John Cush RheumNow( View Tweet)
Links:
Dr. John Cush RheumNow( View Tweet)
